Everyone has a unique combination of human leukocyte antigens (HLAs) in their body that help the immune system identify threats. HLAs were named from the fact that they were first identified on the surface of human leukocytes. Afterward, HLAs were also found on all human cells. HLAs present antigens to immune cells. These HLAs also influence how the immune system attacks cancer cells. Immune checkpoint inhibitors are drugs that can help the immune system fight cancer, but they sometimes cause severe adverse events. In this study, we investigated whether specific HLA genes are related to the development of an adverse event that affects the thyroid in cancer patients treated with immune checkpoint inhibitors. We found an association between three HLA genes (A*26:01, DPA1*01:03 and DPB1*02:01) and the development of the thyroid adverse event. However, larger studies are needed to confirm and generalize these initial exploratory findings.
每个人体内都有人类白细胞抗原(HLA)的独特组合,可帮助免疫系统识别威胁。HLA的命名是因为它们首先在人类白细胞表面上被鉴定。之后,在所有人类细胞上也发现了HLA。HLA将抗原呈递给免疫细胞。这些HLA还影响免疫系统如何攻击癌细胞。免疫检查点抑制剂是可以帮助免疫系统对抗癌症的药物,但有时会引起严重的不良事件。在这项研究中,我们调查了特定的HLA基因是否与免疫检查点抑制剂治疗的癌症患者发生影响甲状腺的不良事件相关.我们发现三个HLA基因(A*26:01,DPA1*01:03和DPB1*02:01)与甲状腺不良事件的发展之间存在关联。然而,需要更大规模的研究来确认和推广这些初步的探索性发现.